Fortress Biotech and Sentynl Therapeutics Fail to Secure FDA Approval for CUTX-101 in Rare Pediatric Menkes Disease on October 02, 2025 biotech Complete CUTX-101 deficiencies Drug Approval Fortress Infrequent manufacturing Menkes disease Pediatric Disorder Sentynl Therapeutics United States Food and Drug Administration +